T1	Participants 108 169	stage I low-grade and intermediate-grade non-Hodgkin lymphoma
T2	Participants 389 508	patients with Stage I non-Hodgkin lymphoma (NHL) who have achieved a complete response (CR) after radiation therapy (RT
T3	Participants 530 610	patients with clinical or pathologic Stage I intermediate-grade or low-grade NHL
